Everolimus in metastatic renal cell carcinoma: preliminary experience from Chang Gung Memorial Hospital.

Chang Gung medical journal Pub Date : 2012-09-01 DOI:10.4103/2319-4170.105478

Wen-Kuan Huang, Chuang-Chi Liaw, See-Tong Pang, Cheng-Keng Chuang, Yang-Jen Chiang, Chun-Te Wu, Ying-Hsu Chang, Hung-Ming Wang, Yung-Chang Lin, Jia-Juan Hsieh, Li-Ying Ou, Shih-I Tsai, Chih-Hsun Yang, Cheng-Ta Yang, John Wen-Cheng Chang

{"title":"Everolimus in metastatic renal cell carcinoma: preliminary experience from Chang Gung Memorial Hospital.","authors":"Wen-Kuan Huang, Chuang-Chi Liaw, See-Tong Pang, Cheng-Keng Chuang, Yang-Jen Chiang, Chun-Te Wu, Ying-Hsu Chang, Hung-Ming Wang, Yung-Chang Lin, Jia-Juan Hsieh, Li-Ying Ou, Shih-I Tsai, Chih-Hsun Yang, Cheng-Ta Yang, John Wen-Cheng Chang","doi":"10.4103/2319-4170.105478","DOIUrl":null,"url":null,"abstract":"Background: Everolimus has been approved for second-line treatment of patients with metastatic renal cell carcinoma (mRCC) after failure of sorafenib or sunitinib. The purpose of this retrospective study was to assess the efficacy and safety of everolimus in Taiwanese patients with mRCC.Methods: Between March 2009 and August 2011, 24 mRCC patients treated with everolimus were analyzed. Prior to everolimus, each patient had received therapy with at least one vascular endothelial growth factor receptor-tyrosine kinase inhibitor. Progression-free survival (PFS) and overall survival (OS) were estimated according to the Kaplan-Meier method.Results: Fifteen patients (62.5%) achieved stable disease. The median PFS was 7.1 months (95% confidence interval, 3.6-10.5 months). The median OS was 20.7 months (95% confidence interval, 5.0-36.4 months). The most frequent non-hematologic adverse events with everolimus were mucositis, rash, epistaxis and pneumonitis.Conclusions: Everolimus is an effective second-line treatment for Taiwanese patients with mRCC. The toxicity is tolerable and manageable.","PeriodicalId":10018,"journal":{"name":"Chang Gung medical journal","volume":"35 5","pages":"402-7"},"PeriodicalIF":0.0000,"publicationDate":"2012-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chang Gung medical journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/2319-4170.105478","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

Abstract

Background: Everolimus has been approved for second-line treatment of patients with metastatic renal cell carcinoma (mRCC) after failure of sorafenib or sunitinib. The purpose of this retrospective study was to assess the efficacy and safety of everolimus in Taiwanese patients with mRCC.

Methods: Between March 2009 and August 2011, 24 mRCC patients treated with everolimus were analyzed. Prior to everolimus, each patient had received therapy with at least one vascular endothelial growth factor receptor-tyrosine kinase inhibitor. Progression-free survival (PFS) and overall survival (OS) were estimated according to the Kaplan-Meier method.

Results: Fifteen patients (62.5%) achieved stable disease. The median PFS was 7.1 months (95% confidence interval, 3.6-10.5 months). The median OS was 20.7 months (95% confidence interval, 5.0-36.4 months). The most frequent non-hematologic adverse events with everolimus were mucositis, rash, epistaxis and pneumonitis.

Conclusions: Everolimus is an effective second-line treatment for Taiwanese patients with mRCC. The toxicity is tolerable and manageable.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

依维莫司治疗转移性肾细胞癌:长庚纪念医院初步经验。

背景:依维莫司已被批准用于索拉非尼或舒尼替尼治疗失败后转移性肾细胞癌(mRCC)患者的二线治疗。本回顾性研究的目的是评估依维莫司对台湾mRCC患者的疗效和安全性。方法:对2009年3月至2011年8月24例接受依维莫司治疗的mRCC患者进行分析。在使用依维莫司之前，每位患者都接受了至少一种血管内皮生长因子受体酪氨酸激酶抑制剂的治疗。根据Kaplan-Meier法估计无进展生存期(PFS)和总生存期(OS)。结果:15例(62.5%)病情稳定。中位PFS为7.1个月(95%置信区间，3.6-10.5个月)。中位OS为20.7个月(95%置信区间5.0-36.4个月)。依维莫司最常见的非血液学不良事件是粘膜炎、皮疹、鼻出血和肺炎。结论:依维莫司是台湾mRCC患者有效的二线治疗药物。毒性是可以忍受和可控的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Chang Gung medical journal

自引率

0.00%

发文量

期刊最新文献

Avian influenza. The diagnosis and treatment of neonatal seizures. Leiomyosarcoma of the adrenal vein. Team innovation climate and knowledge sharing among healthcare managers: mediating effects of altruistic intentions. Serum lipid profile could predict the inception and impacts of violent behaviors among acute psychiatric inpatients.